IP Library Granted Patent US 11,878,012
Granted Patent B2
US 11,878,012 · App. 17/185,031 · Granted Jan 23, 2024

Compositions and methods for treating traumatic brain injury

Inventor: Chase Carver (San Antonio, TX)
Assignee: Board of Regents, The University of Texas System
A61K31/4709A61K31/4184A61K45/06A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,878,012
App. No.
17/185,031
Granted
Jan 23, 2024
Kind
B2
Abstract

Certain embodiments are directed to methods and compositions for treating or preventing seizures in a subject using a therapeutic agent comprising one or more Transient Receptor Potential-Canonical 4/5 channel antagonists sufficient to regulate excitability of neurons in the brain of a subject.

Claims (9)

1. A method of treating a subject that has experienced a traumatic brain injury (TBI) comprising administering to the subject having experienced a_TBI a selective small molecule inhibitor of Transient Receptor Potential-Canonical (TRPC) 4/5 channel.

2. The method of claim 1 , wherein the selective small molecule inhibitor of TRPC4/5 channel is M084 hydrochloride.

3. The method of claim 1 , wherein the selective small molecule inhibitor of TRPC4/5 channel is ML204.

4. The method of claim 1 , wherein the selective small molecule inhibitor of TRPC4/5 channel is administered to the subject by a route selected from among a parenteral, intravenous, intraarterial, intramuscular, intracranial, intraorbital, nasal, or intraventricular route.

5. The method of claim 1 , further comprising administering one or more additional therapeutic agents to the subject.

6. The method of claim 5 , wherein the one or more additional therapeutic agent is selected from among a neuroprotective agent, an anticonvulsant agent, an antiepileptic agent, or a combination thereof.

7. The method of claim 5 , wherein the selective small molecule inhibitor of TRPC4/5 channel is administered to the subject before, at the same time, or after the additional therapeutic agent is administered to the subject.

8. The method of claim 1 , wherein the subject is a human subject.

9. A method of treating a subject that has experienced a traumatic brain injury (TBI) comprising administering to a subject having experienced a TBI a selective small molecule inhibitor of Transient Receptor Potential-Canonical (TRPC) 4/5 channel selected from M084 and ML204.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 2, 2023
From: UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANTONIO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065431/0438 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2021
From: CARVER, CHASE
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 058230/0407 →
Continuity (2)
Provisional Application 62981839 · Feb 26, 2020
Related Publication 20220125779A1 · Apr 28, 2022